Immunotherapy before surgery for recurrent melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have melanoma that has come back after previous treatment, and it is an advanced stage (IIIB, IIIC, IIID, or IV).
- You have already received a type of immunotherapy called anti-PD1 (like nivolumab or pembrolizumab) for your melanoma.
- Your melanoma can be removed with surgery (your surgical oncologist has said it is resectable).
- You are generally healthy enough for daily activities (ECOG score 0 or 1), and your blood counts, liver, and kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This study tests if eating certain prebiotic foods while receiving immunotherapy before melanoma surgery can boost your immune system and improve treatment response. Participants eat study-provided foods and receive standard immunotherapy (ipilimumab with or without nivolumab, or nivolumab with or without relatlimab).
This trial is for people with stage III melanoma that can be surgically removed. It compares one immunotherapy drug to a combination of two, to see which works better before surgery.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.